Physician
Appalachian Regional Healthcare, INC.
Appalachian Regional Healthcare, INC. was paid $26.86M by Medicaid between Jan 2018 and Dec 2024, across 191 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.
33Billing provider infoAPPALACHIAN REGIONAL HEALTHCARE, INC.
MC DOWELL, KY 41647
MC DOWELL, KY 41647
33aNPI1649209263assigned 07/03/2006
33bProvider typeEmergency Medicine Physician
28Total paid$26.86M
24GClaims498,261
24DCodes billed191
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Emergency Medicine Physician providers in Kentucky
Rank by total paid#2 of 91
Median peer was paid$34K
This provider vs. median788×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HARRIS, HOLLIE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 76,959 | $4.50M | |
| 2019 | 66,966 | $3.49M | |
| 2020 | 63,681 | $2.97M | |
| 2021 | 77,371 | $3.86M | |
| 2022 | 77,725 | $3.88M | |
| 2023 | 74,304 | $4.24M | |
| 2024incomplete | 61,255 | $3.91M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 10,305 | 8,590 | $4.87M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 8.1% | 3,063 | 2,707 | $2.17M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.7% | 16,013 | 14,093 | $1.80M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 6.7% | 25,797 | 16,211 | $1.79M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.4% | 3,249 | 2,338 | $1.72M |
| G0378 | Hospital observation service, per hour | 5.1% | 3,012 | 1,444 | $1.36M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4.2% | 22,274 | 17,689 | $1.14M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.9% | 7,442 | 1,957 | $789K |
| 80053 | Comprehensive metabolic panel | 2.8% | 31,123 | 21,633 | $743K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 2.3% | 1,022 | 694 | $618K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.3% | 31,151 | 23,792 | $615K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.3% | 1,996 | 1,735 | $605K |
179 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 5,233 | $388K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 29,202 | $379K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 14,448 | $361K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 6,038 | $338K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 6,079 | $330K |
| 36415 | Collection of venous blood by venipuncture | 1.2% | 59,137 | $328K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 2,543 | $311K |
| 87631 | 1.1% | 2,964 | $302K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.1% | 5,020 | $287K |
| 71045 | Radiologic examination, chest; single view | 1.0% | 5,809 | $278K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.0% | 6,132 | $272K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,491 | $215K |
| 80061 | Lipid panel | <1% | 10,595 | $205K |
| 84484 | <1% | 5,656 | $202K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12,010 | $197K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,195 | $194K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,888 | $192K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,808 | $182K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,951 | $177K |
| 87040 | <1% | 2,578 | $142K | |
| 82607 | <1% | 6,409 | $141K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,625 | $119K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,890 | $113K |
| 81001 | <1% | 12,333 | $113K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,995 | $107K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 8,492 | $103K |
| 83880 | <1% | 2,389 | $101K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,829 | $98K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,053 | $98K |
| 80074 | <1% | 1,378 | $98K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,604 | $92K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,212 | $87K |
| 72100 | <1% | 954 | $84K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,099 | $79K |
| 83690 | <1% | 3,079 | $61K | |
| 81025 | <1% | 2,035 | $60K | |
| 83735 | <1% | 6,985 | $59K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 105 | $54K |
| 83605 | <1% | 1,744 | $51K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 228 | $51K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 756 | $49K |
| 82746 | <1% | 1,973 | $49K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,323 | $45K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 309 | $45K |
| 72131 | <1% | 101 | $45K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,733 | $42K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 164 | $41K |
| 87186 | <1% | 1,803 | $41K | |
| 96376 | <1% | 1,077 | $39K | |
| 82728 | <1% | 1,824 | $38K | |
| 73630 | <1% | 481 | $38K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 704 | $38K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,042 | $37K |
| 82150 | <1% | 2,374 | $36K | |
| 82553 | <1% | 1,312 | $36K | |
| 82550 | <1% | 2,234 | $34K | |
| 83540 | <1% | 2,916 | $32K | |
| 71250 | <1% | 90 | $31K | |
| 82043 | <1% | 3,121 | $31K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,575 | $30K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 83 | $29K |
| 83550 | <1% | 2,181 | $29K | |
| 73564 | <1% | 339 | $29K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 854 | $29K |
| 84439 | <1% | 1,790 | $28K | |
| 73030 | <1% | 432 | $26K | |
| 87077 | <1% | 1,287 | $26K | |
| 97162 | <1% | 376 | $25K | |
| 82652 | <1% | 815 | $25K | |
| 73610 | <1% | 283 | $24K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,475 | $24K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 249 | $23K |
| 93041 | <1% | 878 | $19K | |
| 73562 | <1% | 263 | $19K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 31 | $19K |
| 0100U | <1% | 144 | $18K | |
| 83525 | <1% | 1,074 | $18K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 225 | $18K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 624 | $17K |
| 87522 | Neg quan hep c or qual rna | <1% | 412 | $17K |
| 87076 | <1% | 1,181 | $17K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 15 | $13K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 775 | $13K |
| 85378 | <1% | 623 | $13K | |
| 85610 | <1% | 1,339 | $12K | |
| 84703 | <1% | 493 | $11K | |
| 74022 | <1% | 84 | $11K | |
| 85730 | <1% | 647 | $10K | |
| 82803 | <1% | 135 | $10K | |
| 86038 | <1% | 719 | $10K | |
| 82570 | <1% | 1,096 | $10K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,202 | $10K |
| 86200 | <1% | 637 | $9K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 105 | $8K |
| 87070 | <1% | 336 | $8K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 182 | $8K |
| 74018 | <1% | 106 | $8K | |
| 73130 | <1% | 104 | $8K | |
| 84481 | <1% | 231 | $7K | |
| 84100 | <1% | 825 | $7K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,225 | $7K |
| 36600 | <1% | 183 | $6K | |
| 85652 | <1% | 758 | $6K | |
| 99406 | <1% | 607 | $6K | |
| 72040 | <1% | 70 | $5K | |
| 0002A | <1% | 425 | $5K | |
| 84145 | <1% | 70 | $5K | |
| 90686 | <1% | 249 | $5K | |
| 0001A | <1% | 495 | $5K | |
| 73110 | <1% | 55 | $4K | |
| 86140 | <1% | 259 | $4K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 300 | $4K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 131 | $4K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 12 | $4K |
| 87581 | <1% | 83 | $4K | |
| 87486 | <1% | 83 | $4K | |
| 80076 | <1% | 230 | $3K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 13 | $3K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 104 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,178 | $3K |
| 97533 | <1% | 52 | $3K | |
| 84550 | <1% | 302 | $2K | |
| 84436 | <1% | 122 | $2K | |
| 84403 | <1% | 106 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 57 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 78 | $2K |
| 81002 | <1% | 363 | $2K | |
| 92523 | <1% | 13 | $2K | |
| 73080 | <1% | 17 | $2K | |
| 84480 | <1% | 63 | $2K | |
| 83615 | <1% | 81 | $2K | |
| 86431 | <1% | 210 | $1K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 71 | $1K |
| 84153 | <1% | 53 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 694 | $1K |
| 87590 | <1% | 53 | $1K | |
| 85384 | <1% | 55 | $1K | |
| 86677 | <1% | 46 | $1K | |
| 80069 | <1% | 203 | $983.87 | |
| 90674 | <1% | 48 | $967.81 | |
| 73502 | <1% | 14 | $958.07 | |
| 90715 | <1% | 13 | $811.09 | |
| 84270 | <1% | 43 | $800.67 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 124 | $696.66 |
| 86696 | <1% | 39 | $679.07 | |
| 86702 | <1% | 62 | $595.42 | |
| 90656 | <1% | 29 | $595.31 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 198 | $563.72 |
| 86756 | <1% | 24 | $528.29 | |
| 87634 | <1% | 19 | $432.18 | |
| 84146 | <1% | 25 | $427.38 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 24 | $426.89 |
| 86701 | <1% | 62 | $412.61 | |
| 87807 | <1% | 33 | $407.89 | |
| 0012A | <1% | 54 | $400.19 | |
| 86695 | <1% | 39 | $378.01 | |
| 85379 | <1% | 34 | $368.95 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 18 | $308.22 |
| 84402 | <1% | 15 | $302.40 | |
| 99497 | <1% | 15 | $295.86 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 13 | $285.52 |
| 0011A | <1% | 45 | $269.29 | |
| 88142 | <1% | 12 | $252.60 | |
| 0003A | <1% | 23 | $252.12 | |
| 86803 | <1% | 19 | $228.93 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 37 | $210.96 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 15 | $171.61 |
| 82140 | <1% | 57 | $157.13 | |
| Q2037 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | <1% | 13 | $138.40 |
| 80143 | <1% | 15 | $125.61 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 24 | $108.35 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 14 | $95.08 |
| 82248 | <1% | 18 | $60.79 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 14 | $14.35 |
| A9270 | Non-covered item or service | <1% | 186 | $11.62 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 225 | $0.22 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 181 | $0.09 |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 13 | $0.03 |
| Q0222 | Injection, bebtelovimab, 175 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARRIS, HOLLIE (PRESIDENT AND CEO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.